Grant: Planning and Dissemination Grant - Institute Community Support
University of Calgary
$10,000.00
International Cerebral Amyloid Angiopathy Conference
EF 2019-20
Résumé
Cerebral amyloid angiopathy (CAA) is a brain blood vessel disease caused by deposition of a protein, beta-amyloid, in the walls of blood vessels of the brain. CAA is a common finding at autospy in older persons (ore than 10% of persons age >80 have evidence of moderate or severe CAA) but we have trouble diagnosing it during life. There are no highly sensitive and specific diagnostic tests. The most severely affected patients suffer hemorrhages in the brain or on the brain's surface. Once hemorrhages begin, we can recognize the disease. The prognosis is poor, because the hemorrhages often recur (average 9% risk per year) and are frequently fatal. More insidiously, CAA causes more subtle damage to the brain that increases the risk for dementia. Statistical models indicate that if there were a cure for CAA, 7% of dementia cases would be prevented.
We are applying for support to host the 7th International CAA Conference in Banff, Alberta, Canada on October 1-3, 2020. The Conference Chair is Dr. Eric Smith (University of Calgary), a world-leading expert on CAA. The conference will be attended by 180-200 leading CAA scientists, physicians, graduate students and post-doctoral fellows, staff from organizations such as the International CAA Association (Leiden, Netherlands), Alzheimer Society of Alberta and the Canadian Consortium on Neurodegeneration in Aging, and persons with lived experience with CAA and their care partners. This is the 7th international conference but the first one located in Canada.
The objective of the conference will be to disseminate the latest research on CAA (including basic science and human-based research), share best practices for clinical care and management of persons with CAA, and advance a research agenda to translate basic science discoveries into clinical trials of new treatments.
Programme
Planning and Dissemination Grant - Institute Community Support
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
411943
Name
Smith Eric E
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Planning and Dissemination - INMHA
Projecttitle
International Cerebral Amyloid Angiopathy Conference
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Calgary
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Alzheimer'S Disease; Cerebral Amyloid Angiopathy; Cognition; Stroke
Abstract
Cerebral amyloid angiopathy (CAA) is a brain blood vessel disease caused by deposition of a protein, beta-amyloid, in the walls of blood vessels of the brain. CAA is a common finding at autospy in older persons (ore than 10% of persons age >80 have evidence of moderate or severe CAA) but we have trouble diagnosing it during life. There are no highly sensitive and specific diagnostic tests. The most severely affected patients suffer hemorrhages in the brain or on the brain's surface. Once hemorrhages begin, we can recognize the disease. The prognosis is poor, because the hemorrhages often recur (average 9% risk per year) and are frequently fatal. More insidiously, CAA causes more subtle damage to the brain that increases the risk for dementia. Statistical models indicate that if there were a cure for CAA, 7% of dementia cases would be prevented.
We are applying for support to host the 7th International CAA Conference in Banff, Alberta, Canada on October 1-3, 2020. The Conference Chair is Dr. Eric Smith (University of Calgary), a world-leading expert on CAA. The conference will be attended by 180-200 leading CAA scientists, physicians, graduate students and post-doctoral fellows, staff from organizations such as the International CAA Association (Leiden, Netherlands), Alzheimer Society of Alberta and the Canadian Consortium on Neurodegeneration in Aging, and persons with lived experience with CAA and their care partners. This is the 7th international conference but the first one located in Canada.
The objective of the conference will be to disseminate the latest research on CAA (including basic science and human-based research), share best practices for clinical care and management of persons with CAA, and advance a research agenda to translate basic science discoveries into clinical trials of new treatments.
Competitiondate
201909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Smith, Eric E
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Neurosc Mental Hlth &A~ $10,000~ $0~